Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:10 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 11,377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Withdrawn Phase 2 Interventional

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

NCT07001254
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Romiplostim, Immunosuppressive therapy (IST)
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 2:10 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing a Digital AEP Risk Intervention With Native Women and Communities

NCT06324929
View directory record Official record
Conditions
Alcohol Exposed Pregnancy, Unplanned Pregnancy, Alcohol Use, Unspecified, Contraception Use, Sexual Behavior
Interventions
CARRII Native Rapid Pilot Testing
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 2, 2026, 2:10 AM EST
Completed Not applicable Interventional

Clipping Versus No Hair Removal and the Risk of Surgical Site Infections

NCT00975377
View directory record Official record
Conditions
Surgical Site Infection, Superficial Surgical Site Infection, Deep Surgical Site Infection, Organ/Space Surgical Site Infection
Interventions
Hair clipping
Procedure
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
1,678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Nov 2, 2026, 2:10 AM EST
Completed Not applicable Interventional

Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy

NCT00042731
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lycopene, Multivitamin, Soy isoflavones
Dietary Supplement
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

NCT04111666
View directory record Official record
Conditions
Healthy
Interventions
AL101, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Nov 2, 2026, 2:10 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

NCT03838367
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 2, 2026, 2:10 AM EST
Completed No phase listed Observational

Increasing Patient Experience Survey Responses

NCT04994366
View directory record Official record
Conditions
Patient Satisfaction
Interventions
Thank you card
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Nov 2, 2026, 2:10 AM EST
Recruiting Phase 1 Interventional

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

NCT07317505
View directory record Official record
Conditions
Cancer, Cancer (Solid Tumors)
Interventions
JMT108
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1 Interventional

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

NCT00510445
View directory record Official record
Conditions
Lung Cancer
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Nov 2, 2026, 2:10 AM EST
Completed No phase listed Observational

Imaging Parameters and DME Treatment Response

NCT02637245
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
No intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Nov 2, 2026, 2:10 AM EST
Withdrawn Phase 2 Interventional

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT03704077
View directory record Official record
Conditions
Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
Interventions
Relatlimab + Nivolumab, Nivolumab, Paclitaxel, Ramucirumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Daphne, Alabama • Bakersfield, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Nov 2, 2026, 2:10 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 2, 2026, 2:10 AM EST
Active, not recruiting Phase 1 Interventional

Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors

NCT02789228
View directory record Official record
Conditions
Solid Tumors
Interventions
Tumor associated antigen lymphocytes (TAA-CTL)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
View directory record Official record
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 2, 2026, 2:10 AM EST
Active, not recruiting Phase 2 Interventional

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

NCT05632328
View directory record Official record
Conditions
Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Bruno Bockorny
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1 Interventional

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

NCT04291079
View directory record Official record
Conditions
Cancer
Interventions
SRK-181, anti-PD-(L)1 antibody therapy
Biological
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Fullerton, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

NCT01014962
View directory record Official record
Conditions
Onychomycosis
Interventions
Albaconozole, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 2, 2026, 2:10 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

NCT05746169
View directory record Official record
Conditions
Cancer
Interventions
Health Questionnaires, Specimen sample collection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,576 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Berkeley, California • Fresno, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy

NCT03937505
View directory record Official record
Conditions
Ureter Injury
Interventions
IS-001, No treatment
Drug
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Austin, Texas • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

NCT04086823
View directory record Official record
Conditions
Submental Fat
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1Phase 2 Interventional

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

NCT00064103
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions
Ad5CMV-p53 gene, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Nov 2, 2026, 2:10 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Durvalumab, Tremelimumab, Poly-ICLC
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Nov 2, 2026, 2:10 AM EST